Hiroki Morizono

Hiroki Morizono

Auto-generated profile, based on publicly available information

Hiroki Morizono

Center for Genetic Medicine Research, Children’s National Hospital

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
YYYang Yang
Yang Yang
LWLili Wang
Lili Wang
PBPeter Bell
Peter Bell
DMDeirdre McMenamin
Deirdre McMenamin
ZHZhenning He
Zhenning He
JWJames M Wilson
James M Wilson
In vivo delivery of CRISPR-Cas9 corrects mutation in newborn mouse liver. Many genetic liver diseases in newborns cause repeated, often lethal, metabolic crises. Gene therapy using nonintegrating viruses such as adeno-associated virus (AAV) is not optimal in this setting because the nonintegrating genome is lost as developing hepatocytes proliferate1,2. We reasoned that newborn liver may be an ideal setting for AAV-mediated gene correction using CRISPR-Cas9. Here we intravenously infuse two AAVs, one expressing Cas9 and the other expressing a guide RNA and the donor DNA, into newborn mice with a partial deficiency in the urea cycle disorder enzyme, ornithine transcarbamylase (OTC). This resulted in reversion of the mutation in 10% (6.7–20.1%) of hepatocytes and increased survival in mice challenged with a high-protein diet, which exacerbates disease. Gene correction in adult OTC-deficient mice was lower and accompanied by larger deletions that ablated residual expression from the endogenous OTC gene, leading to diminished protein tolerance and lethal hyperammonemia on a chow diet.

20 July 2011 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
RCRoberto Calcedo
Roberto Calcedo
HMHiroki Morizono
Hiroki Morizono
LWLili Wang
Lili Wang
RMRobert McCarter
Robert McCarter
JHJianping He
Jianping He
JWJames M. Wilson
James M. Wilson
Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.

27 September 2011 in Neurology
Verified
Journal Article
Open access
PDF file
MPM. Prust
M. Prust
JWJ. Wang
J. Wang
HMH. Morizono
H. Morizono
AMA. Messing
A. Messing
MBM. Brenner
M. Brenner
AVA. Vanderver
A. Vanderver
Objective: To characterize Alexander disease (AxD) phenotypes and determine correlations with age at onset (AAO) and genetic mutation. AxD is an astrogliopathy usually characterized on MRI by leukodystrophy and caused by glial fibrillary acidic protein (GFAP) mutations. Methods: We present 30 new cases of AxD and reviewed 185 previously reported cases. We conducted Wilcoxon rank sum tests to identify variables scaling with AAO, survival analysis to identify predictors of mortality, and χ2 tests to assess the effects of common GFAP mutations. Finally, we performed latent class analysis (LCA) to statistically define AxD subtypes. Results: LCA identified 2 classes of AxD. Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features. Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features. Survival analysis predicted a nearly 2-fold increase in mortality among patients with type I AxD relative to those with type II. R79 and R239 GFAP mutations were most common (16.6% and 20.3% of all cases, respectively). These common mutations predicted distinct clinical outcomes, with R239 predicting the most aggressive course. Conclusions: AAO and the GFAP mutation site are important clinical predictors in AxD, with clear correlations to defined patterns of phenotypic expression. We propose revised AxD subtypes, type I and type II, based on analysis of statistically defined patient groups.

19 June 2006 in Human Mutation
Verified
Journal Article
Closed access
PDF file
SYSaori Yamaguchi
Saori Yamaguchi
LBLisa L. Brailey
Lisa L. Brailey
HMHiroki Morizono
Hiroki Morizono
ABAllen E. Bale
Allen E. Bale
MTMendel Tuchman
Mendel Tuchman
Ornithine transcarbamylase (OTC) deficiency is the most common inherited disorder of the urea cycle and is transmitted as an X-linked trait. Defects in the OTC gene cause a block in ureagenesis resulting in hyperammonemia, which can lead to brain damage and death. Three previous mutation updates for the OTC gene have been published, in 1993, 1995, and 2002. The most recent comprehensive update, in 2002, contained 244 mutations including 13 nondisease-causing mutations and polymorphisms. This current update reports 341 mutations, of which 93 have not been previously reported, and an additional 29 nondisease-causing mutations and polymorphisms. Out of the 341 mutations, 149 were associated with neonatal onset of hyperammonemia (within the first week of life), 70 were seen in male patients with later onset of hyperammonemia, and 121 were found in heterozygous females (one unknown). Along with the reported mutations, residual enzyme activities and other pertinent clinical information are included whenever available. Most mutations in the OTC gene are specific to a particular family (“private” mutations). They are distributed throughout the gene, with a significant paucity of mutations in the 32 first codons encoding the “leader” peptide (exon 1 and the beginning of exon 2). Almost all mutations in consensus splice sites confer a neonatal onset phenotype. Using the current molecular screening methods, mutations are found in about 80% of the patients. The remaining patients may have mutations in regulatory domains or mutations deep in the introns, which constitute 98.5% of the genomic sequence. In addition, a phenocopy of OTC deficiency caused by mutations in another unknown gene cannot be excluded. Hum Mutat 27(7):626–632, 2006. Published 2006 Wiley-Liss, Inc.

1 May 2015 in Journal of Genetics and Genomics
Verified
Journal Article
Closed access
LCLjubica Caldovic
Ljubica Caldovic
IAIman Abdikarim
Iman Abdikarim
SNSahas Narain
Sahas Narain
MTMendel Tuchman
Mendel Tuchman
HMHiroki Morizono
Hiroki Morizono

1 January 2010 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
LWLili Wang
Lili Wang
RCRoberto Calcedo
Roberto Calcedo
HWHuan Wang
Huan Wang
PBPeter Bell
Peter Bell
RGRebecca Grant
Rebecca Grant
JWJames M Wilson
James M Wilson
Adeno-associated viral (AAV) vectors hold great potential for liver-directed gene therapy. Stable and high levels of transgene expression have been achieved in many murine models. Systemic delivery of AAV vectors in nonhuman primates (NHPs) that are natural hosts of AAVs appear to be challenging due to the high prevalence of pre-existing neutralizing antibodies (NAbs). This study evaluates the performance of AAV8, hu.37, and rh.8 vectors expressing green fluorescent protein (GFP) from a liver-specific promoter in rhesus macaques. Two of the animals that received AAV8 showed transduction of 24 and 40% of hepatocytes 7 days after systemic vector delivery. Importantly, expression was detected in several animals after 35 days despite the elevation of liver enzymes and development of transgene-specific T cells in liver. Pre-existing low levels of NAbs profoundly impacted the outcome of gene transfer and redirected vector DNA to spleen. We developed a sensitive in vivo passive transfer assay to detect low levels of NAbs to these novel AAV serotypes. Other strategies need to be developed to reduce immune response to the transgene in order to maintain long-term gene expression.